Title | Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis. |
Publication Type | Journal Article |
Year of Publication | 2023 |
Authors | Adaku N, Ostendorf BN, Mei W, Tavazoie SF |
Journal | Cancer Res |
Volume | 83 |
Issue | 18 |
Pagination | 3013-3025 |
Date Published | 2023 Sep 15 |
ISSN | 1538-7445 |
Keywords | Alzheimer Disease, Animals, Apolipoprotein E2, Apolipoprotein E3, Apolipoprotein E4, Apolipoproteins E, Carrier Proteins, Humans, Melanoma, Mice |
Abstract | UNLABELLED: The secreted lipid transporter apolipoprotein E (APOE) plays important roles in atherosclerosis and Alzheimer's disease and has been implicated as a suppressor of melanoma progression. The APOE germline genotype predicts human melanoma outcomes, with APOE4 and APOE2 allele carriers exhibiting prolonged and reduced survival, respectively, relative to APOE3 homozygotes. While the APOE4 variant was recently shown to suppress melanoma progression by enhancing antitumor immunity, further work is needed to fully characterize the melanoma cell-intrinsic effects of APOE variants on cancer progression. Using a genetically engineered mouse model, we showed that human germline APOE genetic variants differentially modulate melanoma growth and metastasis in an APOE2>APOE3>APOE4 manner. The low-density lipoprotein receptor-related protein 1 (LRP1) receptor mediated the cell-intrinsic effects of APOE variants on melanoma progression. Protein synthesis was a tumor cell-intrinsic process differentially modulated by APOE variants, with APOE2 promoting translation via LRP1. These findings reveal a gain-of-function role for the APOE2 variant in melanoma progression, which may aid in predicting melanoma patient outcomes and understanding the protective effect of APOE2 in Alzheimer's disease. SIGNIFICANCE: APOE germline variants impact melanoma progression through disparate mechanisms, such as the protein synthesis-promoting function of the APOE2 variant, indicating that germline genetic variants are causal contributors to metastatic outcomes. |
DOI | 10.1158/0008-5472.CAN-23-1252 |
Alternate Journal | Cancer Res |
PubMed ID | 37335131 |
PubMed Central ID | PMC10740391 |
Grant List | R01 CA184804 / CA / NCI NIH HHS / United States U54 CA261701 / CA / NCI NIH HHS / United States R35 CA274446 / CA / NCI NIH HHS / United States P30 CA008748 / CA / NCI NIH HHS / United States F30 CA257226 / CA / NCI NIH HHS / United States T32 GM007739 / GM / NIGMS NIH HHS / United States |
Submitted by bel2021 on February 16, 2024 - 10:33am